🎉 M&A multiples are live!
Check it out!

Genmab Valuation Multiples

Discover revenue and EBITDA valuation multiples for Genmab and other public comps.

See Genmab Valuation Multiples

Genmab Overview

About Genmab

Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.


Founded

1998

HQ

Denmark
Employees

2.2K+

Website

genmab.com

Financials

LTM Revenue $3.0B

LTM EBITDA $984M

EV

$10.0B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Genmab Financials

Genmab has a last 12-month revenue of $3.0B and a last 12-month EBITDA of $984M.

In the most recent fiscal year, Genmab achieved revenue of $2.3B and an EBITDA of $832M.

Genmab expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Genmab valuation multiples based on analyst estimates

Genmab P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $2.0B $2.3B $3.0B $3.0B XXX
Gross Profit n/a n/a $2.3B XXX XXX
Gross Margin NaN% NaN% 76% XXX XXX
EBITDA $1.0B $832M $962M $984M XXX
EBITDA Margin 51% 36% 32% 32% XXX
Net Profit $420M $771M $608M XXX XXX
Net Margin 21% 34% 20% XXX XXX
Net Debt n/a n/a n/a XXX XXX

Financial data powered by Morningstar, Inc.

Genmab Stock Performance

As of February 7, 2025, Genmab's stock price is DKK 1385 (or $193).

Genmab has current market cap of DKK 88.0B (or $12.3B), and EV of DKK 71.6B (or $10.0B).

See Genmab trading valuation data

Genmab Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$10.0B $12.3B XXX XXX XXX XXX $12.09

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Genmab Valuation Multiples

As of February 7, 2025, Genmab has market cap of $12.3B and EV of $10.0B.

Genmab's trades at 3.3x LTM EV/Revenue multiple, and 10.2x LTM EBITDA.

Analysts estimate Genmab's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Genmab and 10K+ public comps

Genmab Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $10.0B XXX XXX XXX
EV/Revenue 3.3x XXX XXX XXX
EV/EBITDA 10.4x XXX XXX XXX
P/E 15.9x XXX XXX XXX
P/E/Growth 0.8x XXX XXX XXX
EV/FCF 14.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Genmab Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Genmab Valuation Multiples

Genmab's NTM/LTM revenue growth is 17%

Genmab's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $0.7M for the same period.

Over next 12 months, Genmab's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Genmab's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Genmab and other 10K+ public comps

Genmab Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 30% XXX XXX XXX XXX
EBITDA Margin 32% XXX XXX XXX XXX
EBITDA Growth 16% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 49% XXX XXX XXX XXX
Revenue per Employee $1.0M XXX XXX XXX XXX
Opex per Employee $0.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 46% XXX XXX XXX XXX
Opex to Revenue 66% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Genmab Public Comps

See valuation multiples for Genmab public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Genmab M&A and Investment Activity

Genmab acquired  XXX companies to date.

Last acquisition by Genmab was  XXXXXXXX, XXXXX XXXXX XXXXXX . Genmab acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Genmab

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Genmab

When was Genmab founded? Genmab was founded in 1998.
Where is Genmab headquartered? Genmab is headquartered in Denmark.
How many employees does Genmab have? As of today, Genmab has 2.2K+ employees.
Who is the CEO of Genmab? Genmab's CEO is Dr. Jan G. J. van de Winkel, PhD.
Is Genmab publicy listed? Yes, Genmab is a public company listed on CSE.
What is the stock symbol of Genmab? Genmab trades under GMAB ticker.
When did Genmab go public? Genmab went public in 2000.
Who are competitors of Genmab? Similar companies to Genmab include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Genmab? Genmab's current market cap is $12.3B
What is the current revenue of Genmab? Genmab's last 12-month revenue is $3.0B.
What is the current EBITDA of Genmab? Genmab's last 12-month EBITDA is $984M.
What is the current EV/Revenue multiple of Genmab? Current revenue multiple of Genmab is 3.3x.
What is the current EV/EBITDA multiple of Genmab? Current EBITDA multiple of Genmab is 10.2x.
What is the current revenue growth of Genmab? Genmab revenue growth between 2023 and 2024 was 30%.
Is Genmab profitable? Yes, Genmab is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.